Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective multicenter study assessing efficacy of MY004567 Tablets for the treatment of patients with moderately to severely active rheumatoid arthritis

Next Previous
Search
Trial Profile

A prospective multicenter study assessing efficacy of MY004567 Tablets for the treatment of patients with moderately to severely active rheumatoid arthritis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MY 004 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use

Most Recent Events

  • 17 Feb 2025 According to a Wuhan Createrna Science and Technology media release, company received clinical trial approval from the U.S. Food and Drug Administration (FDA) this month for the treatment of rheumatoid arthritis, following its approval in June from the China Drug Administration's Center for Drug Review (CDE) for the innovative drug MY004567.
  • 17 Aug 2023 Planned number of patients changed to 100.
  • 17 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top